Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

4.22USD
29 Mar 2017
Change (% chg)

$0.17 (+4.32%)
Prev Close
$4.05
Open
$4.25
Day's High
$4.40
Day's Low
$4.18
Volume
115,182
Avg. Vol
148,701
52-wk High
$7.59
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Sangamo Therapeutics receives orphan drug designation from the FDA for SB-913 genome editing treatment for MPS II
Wednesday, 1 Mar 2017 08:30am EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics receives orphan drug designation from the fda for sb-913 genome editing treatment for mps ii . Sangamo therapeutics inc - in 2017, sangamo is conducting phase 1/2 clinical trial evaluating sb-913 as an in vivo genome editing treatment for mps ii . Sangamo Therapeutics Inc - sangamo has also submitted an application to FDA for rare pediatric disease designation for sb-913 .Sangamo Therapeutics- data from studies,from clinical trial for fourth lead program, sb-525, a gene therapy approach for hemophilia a, are expected in late 2017 or early 2018.  Full Article

Sangamo therapeutics Q4 loss per share $0.14
Tuesday, 28 Feb 2017 07:00am EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics reports fourth quarter and full year 2016 financial results . Q4 revenue $8.9 million versus $9.1 million . Q4 loss per share $0.14 . Sees FY 2017 revenue $14 million to $19 million . Q4 revenue view $3.9 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Sangamo Therapeutics Inc says expects that its cash, cash equivalents and marketable securities will be at least $60 million at end of 2017 .FY2017 revenue view $22.5 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Therapeutics announces CFO succession
Monday, 27 Feb 2017 04:30pm EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics announces chief financial officer succession . Says Kathy Yi appointed cfo .Sangamo Therapeutics Inc- Kathy Yi succeeds H. Ward Wolff, who will be retiring from company in early march.  Full Article

Sangamo says receives rare pediatric disease designation from FDA for SB-318
Monday, 27 Feb 2017 08:00am EST 

Sangamo Therapeutics Inc : Sangamo therapeutics receives rare pediatric disease designation from fda for sb-318 in vivo genome editing therapeutic for mps i . Sangamo therapeutics inc - in 2017, co is conducting a phase 1/2 clinical trial evaluating sb-318 for mps i .Sangamo therapeutics-submitted application to fda for odd,rare pediatric disease designation for sb-913;co's in vivo genome editing program for mps ii.  Full Article

Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I
Wednesday, 11 Jan 2017 07:30am EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I . Sangamo Therapeutics says data from studies and from planned clinical trial for a fourth lead program, SB-525 are expected in late 2017 or early 2018 .Sangamo Therapeutics says in 2017, plans to conduct first in vivo genome editing clinical trials including phase 1/2 studies for three programs.  Full Article

Sangamo Biosciences enters into a sales agreement with Cowen and Co to sell up to $75 mln of stock
Wednesday, 7 Dec 2016 05:31pm EST 

Sangamo Biosciences Inc :Sangamo Biosciences Inc-On Dec 7, co entered into a sales agreement with Cowen and Company to sell up to $75.0 million of stock, par value $0.01 per share.  Full Article

Sangamo's genome editing program to transfer to Biogen's spin-off Bioverativ
Wednesday, 30 Nov 2016 07:00am EST 

Sangamo Biosciences Inc : Sangamo's genome editing program for hemoglobinopathies to transfer to biogen's spin-off bioverativ .Sangamo's genome editing program for hemoglobinopathies to transfer to biogen's spin-off bioverativ.  Full Article

Sangamo Biosciences receives orphan drug designation from the FDA for sb-fix, the first application of therapeutic in vivo genome editing
Tuesday, 6 Sep 2016 07:00am EDT 

Sangamo Biosciences Inc : Fix, the first application of therapeutic in vivo genome editing .Sangamo Biosciences Inc Says Expects To Initiate A Phase 1/2 Clinical Study (Sb fix-1501) in adult subjects with disease in 2016.  Full Article

Sangamo Bio sees FY 2016 revenue $12 million to $17 million
Wednesday, 3 Aug 2016 04:03pm EDT 

Sangamo Biosciences Inc : Sangamo biosciences reports second quarter 2016 financial results . Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Sees fy 2016 revenue $12 million to $17 million . Q2 revenue $3.7 million versus $8.4 million . Q2 loss per share $0.38 . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Sangamo expects that operating expenses will be in range of $85 million to $95 million for 2016.  Full Article

Sangamo BioSciences announces FDA clearance
Monday, 20 Jun 2016 07:00am EDT 

Sangamo BioSciences Inc : To initiate SB-913-1602 clinical study for MPS II in second half of 2016 .Announces FDA clearance of investigational new drug application for ZFN-mediated genome editing treatment of MPS II.  Full Article

More From Around the Web

BRIEF-Sangamo Therapeutics announces presentation of new data

* Sangamo Therapeutics announces presentation of new data demonstrating significant reduction of TAU expression using proprietary ZFP gene regulation technology